Key Stats for Boston Scientific Stock
- Past-Week Performance: -3.1%
- 52-Week Range: $67.6 to $109.5
- Current Price: $71.2
What Happened?
Boston Scientific (BSX), a medical device company selling cardiac ablation systems, stents, and implantable devices across eight business units, delivered $20.1 billion in 2025 revenue and 22% adjusted EPS growth, yet trades at $71.2 after crashing 35% from its 52-week high of $109.5.
On February 4, the company reported Q4 adjusted EPS of $0.8, beating the $0.78 consensus, but issued 2026 organic revenue guidance of 10% to 11%, well below the 25% EP growth rate the Street had priced in, sending shares down 17.6% in a single session.
FARAPULSE, BSX’s market-leading pulsed field ablation catheter that uses electrical pulses rather than heat or cold to treat irregular heartbeat, grew 35% in Q4 and 73% for the full year, yet the U.S. segment grew flat sequentially as new competitors entered a market BSX now estimates grew only 18% to 20% in Q4, not 25%.
Michael Mahoney, Chairman and CEO, stated on the Q4 2025 earnings call that “we think the market was kind of in an 18% to 20% range, similar to what we developed internally in our plan,” directly challenging the consensus assumption that had inflated Street price targets above $100.
The March 28 ACC Scientific Session presents the first hard test of the recovery thesis, with the CHAMPION trial for WATCHMAN, BSX’s stroke-prevention implant, potentially expanding the indicated patient pool from 5 million to 20 million globally, alongside the Penumbra acquisition close and a long-range plan targeting 10%+ organic growth and 150 basis points of margin expansion through 2028.
Wall Street’s Take on BSX Stock
The 17.6% single-day collapse on February 4 repriced BSX as a structurally impaired growth story, but the company still guides 12% to 14% adjusted EPS growth for 2026, on a business that delivered 22% EPS growth and $20.1 billion in revenue the year prior.
BSX’s normalized EPS grows from $3.06 in 2025 to $3.47 in 2026 and $3.91 in 2027, a trajectory supported by 10% to 11% organic revenue growth guidance and 50 to 75 basis points of operating margin expansion, both of which management reiterated explicitly on March 3 at TD Cowen.
EBITDA margins, which measure operating profitability before non-cash charges and serve as the clearest gauge of earnings quality, expand from 29.8% in 2025 to 30.9% in 2026 and 31.5% in 2027, driven by favorable product mix in higher-margin cardiovascular and oncology divisions as the ACURATE discontinuation headwind annualizes in H2.
The Street has not abandoned BSX despite the sell-off: 25 analysts rate it a buy, 10 rate it outperform, and only 1 holds, with the mean price target at $103.82 as of March 17, implying 45.8% upside from $71.20, a consensus anchored to the CHAMPION trial data presenting at ACC on March 28 and the Penumbra acquisition close.
The analyst target range spans $83 on the low end to $124 on the high, with the low reflecting a scenario where CHAMPION misses and EP share erosion proves more durable, and the high implying a positive CHAMPION outcome expands WATCHMAN’s addressable patient pool from 5 million to 20 million globally.
What Does the Valuation Model Say?
The TIKR mid-case model prices BSX at $120.91 by December 2030, a 69.8% total return on 9.9% revenue CAGR and net income margin expansion from 22.8% in 2025 to 24.8% by 2030, assumptions grounded in the confirmed 10%-plus long-range organic growth plan and three consecutive years of 20%-plus EPS growth preceding the sell-off.
The market is pricing BSX as though EP deceleration is permanent, but FARAPULSE still grew 35% in Q4, faster than every named competitor, in a market BSX itself estimates grew only 18% to 20%.
The TIKR $120.91 target is supported by $4.2 billion in guided 2026 free cash flow and management’s unchanged long-range plan of 10%-plus organic growth, 150 basis points of margin expansion, and leveraged double-digit EPS through 2028.
Management guided 2026 organic growth at 10% to 11% on the same call that triggered the sell-off, and reiterated the same long-range plan numbers without revision on March 3, signaling the deceleration is transitional, not structural.
A negative CHAMPION trial result on March 28 removes the 20-million-patient WATCHMAN expansion thesis and directly impairs the revenue step-up in 2027 that underpins the TIKR model’s $24.6 billion revenue assumption.
The CHAMPION trial presentation on March 28 at ACC is the number to watch: noninferiority on stroke prevention and superiority on bleeding confirms the WATCHMAN TAM expansion and validates the 2027 revenue acceleration built into the mid-case model.
Should You Invest in Boston Scientific Corporation?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up BSX stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Boston Scientific Corporation alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze BSX stock on TIKR for Free →
